ReviewJournal of diabetes investigation2013
Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.
Review in Journal of diabetes investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 77 citations in OpenAlex.
- Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role.Current protein & peptide science · 2025Review
- Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes.Obesity science & practice · 2024Article
- Clinical characteristics of patients with a family history of psoriasis: an observational epidemiological study in Chinese Han population.Frontiers in medicine · 2024Article
- Non-alcoholic fatty liver disease and type 2 diabetes: An update.Journal of diabetes investigation · 2022Review
- Circulating Ism1 Reduces the Risk of Type 2 Diabetes but not Diabetes-Associated NAFLD.Frontiers in endocrinology · 2022Article
- MXD3 Promotes Obesity and the Androgen Receptor Signaling Pathway in Gender-Disparity Hepatocarcinogenesis.Cells · 2021Article
- The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial.Diabetology & metabolic syndrome · 2021Article
- Nonalcoholic fatty liver disease is a risk factor for glucose intolerance onset in men regardless of alanine aminotransferase status.Journal of diabetes investigation · 2021Article
- Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance.Journal of animal science and biotechnology · 2021Review
- The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease.Experimental & molecular medicine · 2021Review
- In search of the optimal management strategy for non-alcoholic fatty liver disease in type 2 diabetes patients.Journal of diabetes investigation · 2021Article
- Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.Journal of oncology · 2021Review
- Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.Frontiers in nutrition · 2021Review
- Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease.Cell & bioscience · 2020Review
- A novel upstream transcription factor 1 target geneBiochemistry and biophysics reports · 2019Article
- Role of Hepatokines in Non-alcoholic Fatty Liver Disease.Journal of translational internal medicine · 2019Review
- The adipokine vaspin reduces apoptosis in human hepatocellular carcinoma (Hep-3B) cells, associated with lower levels of NO and superoxide anion.BMC pharmacology & toxicology · 2019Article
- Kbtbd11 gene expression in adipose tissue increases in response to feeding and affects adipocyte differentiation.Journal of diabetes investigation · 2019Article
- Shedding Perspective on Extracellular Vesicle Biology in Diabetes and Associated Metabolic Syndromes.Endocrinology · 2019Article
- Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.The Indian journal of medical research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) describes a spectrum of liver conditions from simple steatosis, steatohepatitis to end-stage liver disease. The prevalence of NAFLD has been on the rise in many parts of the world, including Asia, and NAFLD is now the liver disease associated with the highest mortality, consequent to the increased risk of cardiovascular diseases and hepatocellular carcinoma. Whereas NAFLD is an independent risk factor for type 2 diabetes, increased hepatic and peripheral insulin resistance contribute to the pathogenesis of both NAFLD and diabetes, which are associated with enhanced cardiovascular risk. Studies in humans and animal models have suggested obesity as the common link of these two diseases, likely mediated by adipose tissue inflammation and dysregulated adipokine production in obesity. In the present review, we discuss recent advances in our understanding of the role of several novel adipokines (adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor-21) in the pathophysiology of NAFLD and diabetes, as well as their use as potential biomarkers and therapeutic targets for dysglycemia in NAFLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.